Related Experiment Video

Updated: Aug 24, 2026

A Protocol for Immunohistochemistry and RNA In-situ Distribution within Early Drosophila Embryo
14:34

A Protocol for Immunohistochemistry and RNA In-situ Distribution within Early Drosophila Embryo

Published on: May 6, 2022

Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2

Xander H T Wehrens1, Stephan E Lehnart, Steven R Reiken

  • 1Department of Physiology and Cellular Biophysics, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

Science (New York, N.Y.)
|April 10, 2004
PubMed

Insights

Sudden cardiac death from ventricular arrhythmias can be prevented. Stabilizing the calstabin2 protein interaction with the RyR2 channel using JTV519 stops calcium leaks that trigger fatal heart rhythms.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Ventricular arrhythmias are a major cause of sudden cardiac death (SCD) in diverse patient populations.
  • Depletion of calstabin2 (FKBP12.6) from the ryanodine receptor-calcium release channel (RyR2) complex leads to intracellular calcium (Ca2+) leak, triggering fatal arrhythmias.
  • This phenomenon is observed in heart failure models and inherited forms of exercise-induced SCD.

Purpose of the Study:

  • To investigate the therapeutic potential of stabilizing the calstabin2-RyR2 interaction.
  • To evaluate the efficacy of JTV519, a 1,4-benzothiazepine derivative, in preventing arrhythmias.

Main Methods:

  • Utilized animal models of heart failure and studies on patients with inherited exercise-induced SCD.
  • Assessed the effect of JTV519 on calstabin2 affinity for the RyR2 complex.
  • Monitored intracellular Ca2+ leak and the occurrence of cardiac arrhythmias.

Main Results:

  • JTV519 significantly increased the binding affinity of calstabin2 to RyR2.
  • This stabilization prevented the aberrant intracellular Ca2+ leak.
  • The treatment effectively inhibited the triggering of fatal cardiac arrhythmias.

Conclusions:

  • Enhancing calstabin2 binding to RyR2 represents a promising therapeutic strategy.
  • Targeting the calstabin2-RyR2 complex may offer a novel approach for managing common ventricular arrhythmias and preventing SCD.

More Related Videos

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...